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Blood-derived smooth muscle cells as a target
for gene delivery
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and Hong Yu, PhD,a,b Miami, Fla
Objective: To examine the feasibility of using blood-derived smooth muscle cells (BD-SMCs) as a target for to deliver
therapeutic proteins.
Materials and Methods: Mononuclear cells (MNC) were isolated from peripheral blood. The outgrowth colonies from
MNC culture were differentiated into BD-SMCs in media containing platelet-derived growth factor BB. Phenotypic
characterization of BD-SMCs was assessed by immunocytochemistry. Cell proliferation, gene transfer efficiency with a
retroviral vector, apoptosis, and the biological activity of the transduced gene product from the BD-SMCs were evaluated
in vitro and in vivo in comparison with vascular derived SMC (VSMCs).
Results: BD-SMCs stained positive for SMC markers. No significant difference was observed between BD-SMCs and
VSMCs in cell proliferation, migration, adhesiveness, and gene transfer efficiency. After BD-SMCs were transduced with
a retroviral vector carrying the secreted alkaline phosphatase gene (SEAP), 174  50 g biologically active SEAP was
produced per 106 cells over 24 hours. After injecting 5  106 cells expressing SEAP intravenously into rabbits, SEAP
concentration increased significantly in the circulation from 0.14  0.04 g/ml to 2.34  0.16 g/ml 3 days after cell
injection (P < .01, n  3). Circulating levels of SEAP decreased to 1.76 g /ml 1 week later and remained at this level
up to 8 weeks, then declined to pre-cell injection level at 12 weeks. VSMC in vivo gene expression data were equivalent.
Conclusion: BD-SMCs have similar characteristics to mature VSMCs and can be used as a novel target for gene transfer
to deliver a therapeutic protein. (J Vasc Surg 2008;47:432-40.)
Clinical Relevance: Cell-based therapy strategies offer the potential to correct a wide spectrum of inherited and
acquired human diseases. Translation to a clinical trial will require a detailed preclinical study to understand the
characteristics of the isolated cells. BD-SMCs are practical and effective targets for ex vivo genetic engineering. They
are obtained with ease by phlebotomy, eliminating the need for surgical tissue explantation. This study tested the
suitability of BD-SMC in vivo as a target for gene therapy. The outcome of the study has direct application in
progenitor cell-based therapy.Progenitor cells outgrown from peripheral blood
mononuclear cells (PB-MNCs) have been detected in adult
peripheral blood of a variety of mammalian species includ-
ing human,1,2 dog,3 rabbit,2,4 guinea pig,2,5 rat,6 and
mouse.7 Endothelial progenitor cells (EPC) isolated from
peripheral blood have been differentiated into endothelial
cells (EC) 8 in culture. Smoothmuscle progenitor cells have
also been isolated from PB-MNCs and differentiated into
cells positive for smoothmuscle cell (SMC)markers in vitro
in the presence of platelet-derived growth factor BB
(PDGF-BB).9,10
Ex vivo gene therapy strategies utilize autologous cells
that are genetically modified prior to re-implantation. In
principal, this approach offers the potential to correct a
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Genetically modified mesenchymal cells such as fibro-
blasts11 and myoblasts,12 as well as vascular SMCs13 have
been reported as vehicles to deliver recombinant proteins
in vivo. However, surgery is required to explant tissue or
a vessel from which the cells can be enzymatically har-
vested.
Blood derived autologous cells hold promise as an
alternative cell resource for cell therapy or as cellular
vehicles that can be genetically engineered to deliver
therapeutic enzymes. EPC from blood have been used to
promote patency in tissue-engineered small-diameter
blood vessels14 and to deliver anticoagulants.15 Isolating
cells from a peripheral blood specimen obviates the need
for surgery. SMC can serve as a candidate for delivery of
a therapeutic protein because the rapid proliferation and
multilayer formation of SMC allow more exogenous
gene product forming units per unit volume than
ECs, which grow as a monolayer. SMCs secrete larger
amounts of extracellular matrix that enable cells to ad-
here more firmly to the graft than ECs.16 This report
explores the potential to use SMC differentiated from
progenitor cells isolated from blood (BD-SMCs) as a
target for gene therapy. The behavior of BD-SMCs in
vitro was compared with mature vascular SMC (VSMC)
digested from surgically excised vein. The behavior of
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retroviral gene transduction compared with VSMC. No
significant difference between BD-SMCs and VSMCs
was found.
MATERIALS AND METHODS
Cell isolation and culture. The animal protocol was
approved by the University of Miami Animal Care and Use
Committee. Peripheral blood (20 ml) was collected from
the ear artery of male NewZealandWhite rabbits into tubes
(TycoHealthcare Group,Mansfield, Mass) containing 15%
ethylenediaminetetraacetic acid (EDTA). The mononu-
clear cells (PB-MNCs) were isolated by density gradient
centrifugation with Histopaque-1077 (Sigma, St Louis,
Mo) and plated in a fibronectin (0.1 mg/ml, BD Bio-
science, Bedford, Mass) coated well with MCDB 131 me-
dium (Invitrogen, Carlsbad, Calif) supplemented with 20%
fetal bovine serum (FBS) and EGM-2 SingleQuots (Cam-
brex, San Diego, Calif) that contains growth factors (hy-
drocortisone, hEGF, VEGF, hFGFB, R3-IGF-1, hEGF,
GA-1000, ascorbic acid, heparin, and gentamicin/ampho-
tericin-B). To promote colony formation, MNC were also
cultured in the same medium described above plus 100
ng/ml stromal cell-derived factor-1 (SDF-1 ) (R&D
Systems, Minneapolis, Minn) or 10 nM fluvastatin (To-
ronto Research Chemicals Inc, Ontario, Canada) for 2
weeks. Media were changed 3 days after initial plating to
remove the unattached cells. After cultured for 2 weeks,
colony-forming cells were passed and subsequently cul-
tured in MCDB 131 supplemented with PDGF-BB (50
ng/mL, R&D Systems) and 20% FBS to induce SMC
differentiation. The resultant BD-SMCswere then cultured
in Williams’ medium (Invitrogen) containing 20% FBS (no
more PDGF-BB) for further characterization.
To examine if the BD-SMCs are terminally differenti-
ated, BD-SMCs were grown to confluence in MEM sup-
plemented with 10% FBS, 7  103 -Glycerophosphate
(-GP), 0.2 mM ascorbic acid, and 10 nM dexamethasone
(Sigma) for 14 days to allow osteoblast differentiation. For
EC differentiation, out-growth cells or BD-SMC were
cultured in MCDB131 supplemented with VEGF and 20%
FBS for 14 days.
Rabbit VSMCs were isolated from surgically harvested
jugular veins by collagenase digestion as described previ-
ously.17 The VSMCs were then cultured in Williams’ me-
dium (Invitrogen) containing 20% FBS, L-glutamine (2
mM), and antibiotics. Both BD-SMC and VSMC were
studied and used at passage of 2-5.
Phenotypic characterization of BD-SMC. Morphol-
ogical appearance and immunohistochemistry were used to
define smoothmuscle cell phenotype. Primary antibodies were
used against CD34 (Santa Cruz Biotechnology, Santa
Cruz, Calif),  smooth muscle actin (SMA) (Calbiochem,
La Jolla, Calif), calponin (Sigma, Saint Louis, Mo), and
smoothmuscle heavy chain (SMHC) (Dako Corp, Carpen-
teria, Calif). A nonspecific isotype-matched IgGwas used as
a negative control. Primary antibodies were detected with
the DAKO LASB 2 Kit (Dako Corp), which uses biotinyl-ated secondary antibody, streptavidin peroxidase, and its
enzyme substrate diaminobenzidine tetrahydrochloride
(DAB; Vector Laboratories, Burlingame, Calif). For deter-
mination of acetylated low density lipoprotein (Ac-LDL)
uptake as amarker for endothelial cells, cells were incubated
with Dil-Ac-LDL (10 g/ml) (Biomedical Technologies
Inc, Stoughton, Mass) for 4 hours at 37oC.
Cell proliferation assay. Both BD-SMCs and VSMCs
at a similar passage were plated at a density of 1 104 cells
per well in a 24-well plate and incubated 24 hours with
serum-free Williams’ medium for growth arrest. The cells
were then cultured with Williams’ media plus 20% FBS.
The cell number in each well was counted continuously for
8 days, along with trypan blue staining to eliminate dead
cells. Cell growth doubling time was calculated with the
formula: DT  t/ln(N1/N2), where t is the time for the
cells to grow from cell number counted at time 1 (N1) to
cell number at time 2 (N2). Cells grow exponentially dur-
ing day 3 and day 5 so the cells numbers were counted at
day 3 and day 5 for the calculation of the doubling time
with t  48 hours in the equation.
Cell migration assay. A modified Boyden-chamber
assay was used to study SMC migration.18 BD-SMC and
VSMC were plated on top of transwell filter inserts
(Costar Corning, Corning, NY) inside a 24-well plate.
After cultured in serum free medium for 48 hours, 5%
FBS was added to the medium in the lower chamber,
followed with overnight incubation. The total cells and
the cells that had migrated to the lower surface were
counted separately to calculate the migration rate. All
assays were run in triplicate.
Apoptosis assay. Cells from passage 10 were grown in
complete media overnight in six well plates at a seeding
density of 5  105 per well. The cells were washed twice
with phosphate-buffered saline (PBS) and fixed in 4% para-
formaldehyde for 30 minutes. The fixed cells were rinsed
twice with PBS and incubated in 1 g/ml 4=-6-Diamidino-
2-phenylindole (DAPI) solution (Sigma) for 30 minutes.
Apoptotic cells were identified under fluorescence micro-
scope by their white condensed pyknotic nuclei. The per-
cent of apoptotic cells was calculated as apoptotic cells
versus total cells.
Retroviral vectors and cell transduction. The
replication-incompetent murine leukemia virus (MuLV)
derived viral vectors, pseudotyped with the vesicular stoma-
titis virus G envelope glycoprotein (VSV-G), were used to
mediate gene transfer into the SMC.19 LPCSEAP is a
retroviral vector carrying the human secreted alkaline phos-
phatase (SEAP) gene whose expression is controlled by the
cytomegalovirus (CMV) promoter. Plasmid pLPCSEAP
was generated by inserting the Hind III/Xba I fragment of
pSEAP2 Basic (Clontech, Mountain View, Calif) into vec-
tor pLPCX (Clontech) Hind III/Avr II sites. Viral vector
supernatants with titers of 1 – 5  106 colony forming
unit per ml (cfu/ml) were generated as previously
described20 from producer cell lines 293/GPG/
G1nBgSvNa and 293/GPG/pLPCSEAP for transfer of
genes encoding for nuclear-localized -galactosidase (-
he PB
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and VSMC with viral vectors G1nBgSvNa and LPCSEAP
was performed using the multiplicity of infection (MOI) of
approximate 100. The transduced cell populations were
named SMC/lacZ and SMC/SEAP, respectively, after
drug selection with either G418 (Gibco BRL) or puromy-
cin, respectively.
Cell retention assay. A pulsatile in vitro flow circuit
as described20 was used to evaluate retention of cells
grown on the surface of a polytetrafluoroethylene
(PTFE) graft. BD-SMCs and VSMCs, transduced with
lacZ gene, were grown on the fibronectin coated PTFE
graft (5-mm internal diameter) for 48 hours, and then
exposed to a pulsatile flow circuit of MCDB 131 medium
for 60 minutes at 500 ml/min with a shear stress of 6.1
dyne/cm2. After this flow exposure, the graft segments
were removed from the pump and rinsed with PBS. Both
pre-flow and post-flow grafts were fixed with 10% form-
aldehyde. The grafts were stained with X-gal to visualize
the seeded cells as described.16 The number of residual
cells were counted by use of a microscope and expressed
as cell density in cells per millimeters squared.
SEAP quantification. SEAP concentration in col-
lected samples was evaluated using the ELISA based Great
EscAPe Detection Kit (Clontech). Samples include the
conditioned medium from cell cultures and the serum from
the rabbits. After centrifugation at 12,000  g for 2 min-
utes to remove any debris, samples (15 l) were mixed with
dilution buffer (45 l) in a 96-well plate, and were incu-
a b
d e
Fig 1. In vitro differentiation of peripheral blood mono
cells. A few attached PB-MNCs grew out (a) and formed
into SMC-like cells (c) after cultured in medium contain
immunostained with fluoresceinisothiocynate conjugated
(e) and lectin binding (f) showed EPC characteristic of tbated at 65°C for 30 minutes to eliminate the endogenousalkaline phosphatase activity, followed by addition of assay
buffer (60 l) and incubation for 5 minutes at room temper-
ature. The disodium 3-(4-methoxyspiro{1,2-dioxetane-3,2=-
(5=-chloro)tricyclo[3.3.1.1 3,7]decan}-4-yl) phenyl phos-
phate (CSPD) substrate (1.25 mM, 60 l/well) in
chemiluminescence enhancer buffer was added to each
sample and incubated for 10 minutes at room temperature.
The intensity of the chemiluminescent signal was deter-
mined by a luminometer (Veritas Microplate Luminom-
eter, Sunnyvale, Calif).
In vivo cell infusion. Confluent cells (5. 0  106
cells) in culture were trypsinized, washed two times with
PBS, and then resuspended in 10 ml PBS. Rabbits were
anesthetized with a mixture of ketamine (35 mg/kg) and
xylazine (10 mg/kg). The ear vein was catheterized, and
cells suspension was infused. Blood samples were obtained
before infusion, then 3 days after cell infusion and weekly
thereafter. The serum was collected and frozen for SEAP
analysis. All specimens were analyzed together at the end of
the experiment.
Statistical analysis. Experimental values were ex-
pressed as mean  standard deviation. Statistically signifi-
cant differences between groups were compared using
2-tailed Student t test. Significance was attributed to a
P value of less than .05.
RESULTS
Colony formation of PB MNCs. MNCs (2.3 
0.52  107, n  26) were isolated from 20 ml rabbit blood
c
f
ar cells (PB-MNC) into smooth muscle cell (SMC)-like
ies after 2 weeks in culture (b). They were differentiated
DGF-BB for 14 days. The outgrowth colony cells were
body against CD34 (d). Fluorescent Dil-ac-LDL uptake
-MNC (original magnification: 100).nucle
colon
ing P
antiand cultured in a fibronectin coated plate. After 2-week cul-
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cultures resulted in outgrowth colonies (range, 1-35) (Fig 1,
b). The attached MNCs stained positive for progenitor
markers CD 34 (Fig 1, d) and CD 133 (data not shown),
and are also positive for EC markers: acetylated-LDL up-
take (Fig 1, e) and lectin binding (Fig 1, f).
To increase the efficiency of colony formation from the
PB-MNCs, MNCs were cultured in the presence of SDF-1
or fluvastatin. Both have been reported to increase EPC
survival.21-23 More attached MNCs were observed when
they were cultured in the presence of SDF-1 or fluvastatin
(201  55 and 172  37 cells/mm2, respectively) com-
pared with that without treatment (118  34 cells/mm2,
P  .05, n  3) (Fig 2), but colony formation did not
increase (data not shown). Neither SDF-1 nor fluvastatin
induced colony formation if the same batch of blood did
not generate a colony after regular culture. Treating the
no-colony-yield rabbits with granulocyte-colony stimulat-
ing factor (G-CSF) resulted in fivefold increase in white
blood cells and onefold increase in MNC, but did not
induce colony formation.
Differentiation and characterization of BD-SMC.
To differentiate the outgrowth colony forming cells (OG-
CFC) into SMCs, the cells were cultured in medium con-
taining PDGF-BB (50 ng/ml). OG-CFCs grew into a
spindle-shaped appearance (Fig 1, c) with a “hill and valley”
morphology suggestive of SMC after being cultured in
PDGF-BB for 14 days. These cells were named blood
Fig 2. Effect of statin and stromal cell-derived factor (
mononuclear cells (PB-MNCs) were cultured in MNC c
SDF-1, and (c) fluvastatin. The attached MNCs were stai
under fluorescence microscopy. B, Relative MNC numb
.05 vs control (n  3) (original magnification: 200).derived SMCs (BD-SMCs).The differentiated BD-SMCs were immunostained
with antibodies against SMC markers. The original OG-
CFCs were negative for -SMA (Fig 3, a), calponin (Fig 3,
e), and smooth muscle heavy chain (SMHC) (Fig 3, i).
After being cultured with PDGF-BB enriched medium for
14 days, the resultant BD-SMCs stained positively for
-SMA (Fig 3, b), calponin (Fig 3, f), and MHC (Fig 3, g),
similar to the control VSMCs (Fig 3, c, g, and k) while ECs
were stained negatively for all these SMCmarkers (Fig 3, d,
h, and l). The expression of -SMA and SMHC was con-
firmed at themRNA level by RT-PCR analysis of total RNA
isolated from BD-SMC using EPC as a negative control.
BD-SMCs were negative for CD 34 immunostaining (data
not shown). They, like VSMCs, did not uptake acetylated-
LDL or bind lectin (data not shown). These data indicate
the EPC characteristics were lost after the cells differenti-
ated into BD-SMCs in the presence of PDGF-BB.
To examine if BS-SMCs can be further differentiated,
BD-SMCs were cultured for 2 weeks in a medium that
induces progenitor cell differentiation into either EC or
osteoblasts. The resultant cells were negative for DiI-Ac-
LDL uptaking and von Kossa staining, a characteristic for
osteoblasts (data not shown). The data suggest BD-SMCs
are terminally differentiated.
Proliferation and migration of BD-SMC. BD-SMCs
had similar growth rates as VSMC of the same passage (Fig 4,
A). The doubling times for BD-SMC and VSMC at the early
passages are 19.2  1.2 hours and 19.1  0.6 hours,
-1 on mononuclear cells (MNCs). A, Peripheral blood
medium with additional of (a) control: no additive, (b)
ith Dil-ac-LDL at the 10th day of culture and visualized
he three groups described in (A). Asterisk indicates PSDF)
ulture
ned w
er in trespectively (P 	 .05, n  3). SMC mobility was analyzed
(c), (g
trol,
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BD-SMC migrating through a porous membrane (29 
3%) was not significantly different to VSMC (31  4%) (P
Fig 3. Characterization of blood-derived smoothmuscl
cells from MNC culture (a), (e), and (i), and the differe
antibodies against SMC markers: smooth muscle -actin
muscle heavy chain (SMHC, lower panel). Vascular SMC
vein were similarly stained as a positive and negative con
Fig 4. Proliferation andmigration of smoothmuscle cells (SMC).
A, Cell proliferation was measured by counting the cell number
daily after the culture medium was switched from serum free to
20% FBS. B, Migration in a Boyden chamber. The percentage of
migration was expressed as the ratio of migrated cells on bottom
side to the total number of cells on both sides. No significant
difference in either proliferation or migration was observed be-
tween blood-derived smooth muscle cells (BD-SMC) and vascular
derived SMC (VSMC) (P 	 .05, n  3).	 .05, n  3) (Fig 4, B).The BD-SMCs can be passed approximately 10 pas-
sages. After that, the cells gradually stop growing. The
percentage of apoptotic BD-SMCs at passage 10 (11 2%)
is significantly higher than that at passage 3 (4 2%, n 3,
P  .05). The increase of apoptotic cells in BD-SMCs at
different passages is similar to that of VSMCs (Fig 5).
Cell retention. To study the adhesiveness of BD-
SMCs, cells were seeded on a PTFE graft and exposed to in
vitro flow for 60 minutes. Most of the BD-SMCs were
retained on the surface of PTFE grafts after exposure to this
flow. The cell retention rate of BD-SMCs (92.5 1.5%) is
not significantly different from that of VSMCs (89.1 
2.6%, n  3, P 	 .05).
Transduction efficiency. To study the feasibility of
using BD-SMCs as a target for genetic engineering, BD-
SMCs were transduced in vitro with VSV-G pseudo-typed
MuLV vector carrying the lacZ gene. The efficiency of
retroviral transduction of BD-SMCs (90  2%, n  3) was
similar to that of VSMC (86  1%, P 	 .05, n3) (Fig 6,
A). Retroviral transduction does not affect the SMC char-
acter of BD-SMC. They were still -actin and calponin
positive after the transduction.
The stability of transgene expression was determined
by examining the percentage of -galactosidase positive
cells after passages of transduced SMCs. The percentage of
-galactosidase positive cells slightly decreased from 90% at
passage 2 to 80% at passage 10 (Fig 6, B). No significant
difference on the transgene expression after the passages
was observed between BD-SMCs and VSMC.
Gene expression in vitro and in vivo. SEAP was used
as a marker to analyze the expression of transgene expres-
(BD-SMC) by immunostaining. The outgrowth colony
d BD-SMCs (b), (f), and (j) were immunostained with
MA, upper panel), calponin (middle panel), and smooth
), and (k), and EC (d), (h), and (l) isolated from jugular
respectively (original magnification: 100).e cells
ntiate
(-Ssion from BD-SMCs both in vitro and in vivo. The concen-
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SMCs/SEAP cells was 173  32 g/106 cells/24 hours,
which is similar with that of VSMC (213  16 g/106
cells/24 hours, P  .70, n  3)(Fig 7, A).
After intravenous infusion of the BD-SMCs/SEAP (5
106 cells per animal) into a rabbit, SEAP was detected in the
blood. At 3 days postinjection, the circulating SEAP concen-
tration increased to 2.34  0.63 g/ml from 0.14  0.04
g/ml before cell injection (P  .01, n  3). Circulating
levels of SEAP decreased to 1.76 g /ml 1 week later and
remained at this level up to 8 weeks, then declined to pre-cell
BD-SMC    
P3
P10
0%
4%
8%
12%
16%
BD-SM
P 3
P 10
Pe
rc
en
ta
ge
A
B
Fig 5. SMC apoptosis. A, 4’-6-Diamidino-2-phenylind
points at white condensed pyknotic nuclei) after blood-der
derived SMC (VSMC) (b) or (d) were passed for th
magnification: 400). B, The percentage of apoptotic B
that at passage 3 (4  2%, n  3, P  .05). The increase
to that of VSMCs.injection SEAP level (0.12  0.04 g/ml) at 12 weeks.Similar SEAP expression pattern was detected from blood of
3 rabbits injected with VSMCs/SEAP (Fig 7, B).
DISCUSSION
This study explored the potential of BD-SMCs as a
target for gene therapy compared with VSMCs. VSMCs are
effective targets for intravascular gene therapy strategies,
but a surgical operation to explant a vein is required to
isolate autologous VSMC for ex vivo manipulation. A
practical alternative is to isolate progenitor cells from circu-
lating blood and differentiate them into smoothmuscle like
                      VSMC
VSMC
API) staining was used to detect apoptotic cells (arrow
smooth muscle cells (BD-SMC) (a) and (c), or vascular
(top panel) and 10 (bottom panel) passages (original
Cs at passage 10 (11  2%) is significantly higher than
optotic cells in BD-SMCs at different passages is similar    
C
ole (D
ived
ree
D-SM
of apcells. In humans, BD-SMCwill have a significant advantage
een t
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vessels. Simple phlebotomy and a gradient centrifugation
will result in PB-MNC that then can be cultured and
differentiated into BD-SMC. These procedures can be
automated and completed in a closed system, eliminating
contamination. In contrast, vein harvesting depends on
tissue availability and requires surgery. Dissociation of cells
from vein needs more hands-on manipulation and more
chance for contamination. Blood derived cells may be kept
in the undifferentiated stage, which will have progenitor
characters and be passed for more generations, and yield
more cells for therapeutic use. In contrast, VSMC can only
be passed 5-7 passages and yield limited number of cells. In
this study, the feasibility of using BD-SMCs from putative
smooth muscle progenitor cells as a target cell for gene
transfer and expression in vivo was demonstrated.
BD-SMCs are less traumatic to obtain compared with
VSMC from a vessel that needs to be surgically explanted.
Simple phlebotomy and a gradient centrifugation will result
in PB MNCs that can be cultured to yield outgrowth
colony forming cells (OG-CFC). However, the number of
outgrowth colonies reported in the literature is variable.
Griese et al reported that the number of colonies ranged
between 5 and 30 per 50 ml blood from rabbit.24 Simper
et al reported six to eight colonies per MNC sample from
healthy young men and women grew out.9 None of them
0%
20%
40%
60%
80%
100%
P2
Pe
rc
en
ta
ge
A
B
Fig 6. Retroviral transduction efficiency and stability of
(BD-SMCs) (left) and vascular derived SMC (VSMCs) (
bearing lacZ gene. The cells with blue-stained nucleus ar
magnification:100). B, The number of -gal positive c
slightly after passages, but no significant difference betwreported failure to obtain a colony from the blood. Ojeda-Uribe et al reported that no outgrown stromal progenitor
cells were obtained from culture of PB MNCs of 17 pa-
tients with solid tumors and hematological malignancies.25
Our study shows that there was a 33% chance that no
colony would grow out from the attached PB-MNCs iso-
lated from 20 ml of rabbit blood after 2-week culture.
Colony formation would be more likely if higher volumes
of blood (50-100 ml) could be drawn, as is possible in the
human being.
Colony formation could be affected bymany factors. Age,
sex, health situation, diet, habits, and menstrual status impact
the number of circulating progenitor cells. Culture medium
(growth factors, composition) will also influence BD-SMC
yield. It has been reported that statins and SDF-1 increase the
number of adherent EPCs.21-23 In the present study, the
attached MNCs did increase 1.7-fold and 1.5-fold in the
presence of SDF-1 or statin, respectively in comparison with
untreated MNC group (Fig 2). However, adding SDF-1 or
fluvastatin into the culture medium did not induce colony
formation from rabbit blood that did not initially have out-
growthMNCcolonies. Treating the animal withG-CSF prior
to phlebotomy resulted in an increase in white blood cells and
MNC, but failed to yield colony formation. G-CSF treatment
may increase only the hematopoietic progenitor cells, but not
the number ofmesenchymal stemcells in blood. Interestingly,
the rabbits that initially did not yield any colony from their
P8 P10
Passage
BD--SM C
VSM C
gene expression. A, Blood-derived smooth muscle cells
) have similar transduction efficiency with MuLV vector
ones successfully transduced at passage 3 (P3) (original
the LacZ transduced BD-SMCs and VSMCs decreased
he groups was observed (P 	 .05, n  3).trans
right
e the
ells inMNC culture generated more than 30 colonies after they
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not shown). Why some rabbits failed to yield out growth
MNCcolonies fromaphlebotomy specimen is unknown.The
composition of cells recovered from the buffy coat after the
gradient centrifugationmay vary each time. It is not clearwhat
kindof progenitor cells out-growing from the attached cells to
form the colony. Anecdotally, a blood sample from a dog that
did not yield colonies following PB MNC culture resulted in
approximately 100 colonies from 50 ml blood 1 month after
implantation of a stent graft into its abdominal aorta. Perhaps
arterial injury may induce the mobilization of these MNC
progenitor cells into the circulation. Study of the mechanism
of MNC mobilization will benefit the therapeutic model
proposed within our project and may provide insight into
disease evolution and repair of injury.
OG-CFCs have multidifferentiation potential. De-
pending on the culture conditions, they are able to be
differentiated into osteoblasts, reticular cells, lipocytes,
chondrocytes, and fibroblasts.2,6,26 OG-CFCs were differ-
entiated into SMC by culturing them in medium contain-
ing PDGF-BB. OG-CFCs initially do not express classic
SMC markers but do express EPC makers: CD34, LDL-
uptaking, and lectin binding (Fig 1, d, e, and f), which are
absent from mature SMC. After exposure to PDGF-BB for
2 weeks, OG-CFCs expressed the classic SMC markers
(Fig 3) and no longer expressed the endothelial markers
(LDL-uptake and CD34, data not shown). This indicates
they differentiated into mature SMC.
Krebsbach et al reported that bone marrow stromal
cells used as vehicles for gene delivery formed new bone in
an in vivo osteogenic assay.27 In the present study, cultur-
ing BD-SMC with either osteoblasts or EC inducing me-
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 2 4 6 8 10 12 14
Weeks after cell injection
BD-SMC
VSMC
SE
AP
 
Co
nc
en
tr
at
io
n
 (u
g/
m
l)
0
50
100
150
200
250
300
CMSVCMS-DBS
EA
P 
co
n
ce
n
tr
at
io
n 
( u
g/
10
6 
ce
lls
)
A
B
Fig 7. Transgene expression in vitro and in vivo. A, Secreted
alkaline phosphatase gene (SEAP) concentration in the cell culture
media of blood-derived smooth muscle cells (BD-SMCs) and
vascular derived SMC (VSMCs), which have been retrovirally
transduced with SEAP gene. B, SEAP concentrations in blood
after i.v. injection of BD-SMC/SEAP (open squares) and VSMC/
SEAP (filled squares) into rabbits.dium for 2 weeks did not alter BD-SMCs phenotype. Theresultant BD-SMCs did not stain for the markers of osteo-
blasts or EC but remained positive for SMC markers. This
indicates that the BD-SMCs are stable and are terminally
differentiated cells.
The growth profile of differentiated BD-SMCs is similar
to VSMC. They proliferate readily in vitro (Fig 4, A). The
doubling time of BD-SMC is about 19 hours, and they were
able to be extended to 10 passages in this study. There are
approximately 3 to4doubling times during the interval of 3 to
4 days between two passages. This agrees with previous report
that smooth muscle outgrowth cells had a capacity for ex-
tended growth in culture over 40 doublings.9
The adhesiveness of BD-SMC is also similar to VSMC.
This property is important for cell seeding on grafts to deliver
therapeutic proteins. Our previous studies16,20 demonstrated
that VSMC can improve endothelial cell retention on polytet-
rafluoroethylene grafts in vivo. A stent graft suffused with
engineered VSMC is a potential vehicle for therapeutic
gene delivery into the blood stream.13
The differentiated BD-SMCs can be efficiently trans-
duced with retroviral vectors (Fig 6, A). Production of the
transgene fromBD-SMC is high, and similar to production of
the same transgene fromVSMC (Fig 7,A). The expression of
transduced genes from BD-SMCs is stable in vitro for at least
10 passages (Fig 6, B). The in vivo expression of the trans-
ducedmarker gene SEAP fromBD-SMCs lasted 8weeks after
the transduced cells were injected i.v. into the circulation.
These data demonstrated that the engineered BD-SMCs con-
tinuously secreted the product of transduced gene into the
circulation. Subsequently, circulating SEAP levels declined to
a background level at the 12th week of the study (Fig 7, B).
The gene expression pattern of BD-SMCs is similar to that of
VSMCs both in vitro and in vivo. These results agree with the
data reported by Clowes’ group stating that gene expression
from genetically engineered VSMC peaks at day 10 and re-
turns to background levels 1 month after cell implantation.28
The reasons for the lack of persistent high level SEAP secre-
tion are unknown. Potential causes include clearance of the
injected cells, inactivation of the viral promoter,29,30 and
development of anti-SEAP antibodies, as in the case of factor
VIII expression in canine.31
BD-SMC can be used for graft engineering through
cell seeding on a graft to achieve sustained drug delivery.
They can also be directly implanted subcutaneously to act
as a depot for designed protein expression. Engineered
SMC can also be injected i.v. as reported in this study. A
weakness of i.v. infusion of cells is the inability to retrieve
the injected cells. The seeded SMC on a graft could poten-
tially compromise small diameter lumena (5 mm diame-
ter). For these smaller vessels, transduction of SMC with
genes that can regulate the proliferation of SMC could be a
way to control the growth of implanted SMC. We have
demonstrated that seeding eNOS gene transduced SMCon
PTFE graft had minimal neointima growth.32 SMC could
be transduced with a suicide gene (eg, thymidine kinase
gene33) before injection, so that the engineered cells inside
the body can be eliminated by administration of a drug
(ganciclovir).
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In conclusion, a range ofMNC outgrowth colonies can
be isolated from peripheral blood. A third of the time, no
outgrowth colonies were isolated. SMCs differentiated
from these putative smooth muscle progenitor cells have
similar characteristics as mature SMC isolated from a vessel.
They can continuously secrete retrovirally engineered
SEAP in vivo for up to 8 weeks. They can be used as a novel
cell target for gene transfer to deliver therapeutic proteins
without having to do surgery to harvest donor tissue.
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